• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

ZEG Berlin GmbH

Zentrum für Epidemiologie und Gesundheitsforschung

  • Home
  • Expertise
    • Real-World Evidence
    • Non-interventional study design
    • Post-authorization safety studies
    • Post-authorization efficacy studies
    • Cohort studies
    • Case-control studies
    • Medical Devices
    • Diagnostic tools
      • Research team
    • Data collection instruments
  • Services
    • RWE Services
    • Crisis Management
    • Consulting
    • Data Management and Biostatistics
    • Medical Writing
    • Study Management
    • Quality Assurance
    • Pharmacovigilance
  • Library & News
    • News/Conferences
    • Publications
  • About Us
    • Who We Are
      • Management Board
      • Executive Team
      • Project Management Team
    • History
    • Careers
    • Data Protection Information
  • Contact

Marc Pignot

Chief Strategy Officer, Head of Real-World Evidence & Safety Data Analytics

Dr. Marc Pignot joined ZEG Berlin to lead the implementation and development of Real-World Evidence & Safety Data Analytics.

Marc has more than 20 years of experience in the pharmaceutical and CRO business. As Chief Strategy Officer, he is establishing a strong secondary data stream to complement and combine with ZEG Berlin’s long-established primary data business. Real-World Evidence and services bridge the growing need for leading-edge secondary data collection with ZEG Berlin’s classical studies for post-authorization, safety, and effectiveness.

Marc Pignot served as Director of Real-World Evidence, and global consulting at Kantar Health, and as a Director at Kendle, now Syneos Health, a global CRO. He was responsible for conducting global clinical trials and Late Phase programs in the main therapeutic areas.

He also worked on Diagnostic Imaging and Medical Device Studies at Amersham Health and GE Healthcare. Before moving to clinical research, Marc worked with Aventis Pharmaceutical’s global research center focusing on functional genomics and proteomics.

Marc Pignot holds a PhD in Bio-Organic Chemistry from the Max Planck Institute of Molecular Physiology and completed postdoctoral training in nucleic acid chemistry at the University of Frankfurt/Scripps Research Institute (La Jolla).

  • share 
  • tweet 
  • share 
  • share 

Publications

O'Kelly James, Bartsch Robert, Kossack Nils, Borchert Julia, Pignot Marc, Hadji Peyman, Real-world effectiveness of osteoporosis treatments in Germany. Arch Osteoporos. 2022; 10.1007/s11657-022-01156-z.
Ding Bo, Pignot Marc, Garal-Pantaler Elena, Villinger Beate, Desta Barnabas, Schmidt Katharina, Golam Sarowar, Stirnadel-Farrant Heide, Schwarting Andreas, Clinical Characteristics, Health Care Resource Utilization, and Costs Associated With Flares in Patients With Systemic Lupus Erythematosus in Germany Ann. Rheum. Dis. - EULAR 2022 Annual European Congress of Rheumatology, June 1–4. 2022;
N Hunnicutt Jake, Schultze Michael, Garal-Pantaler Elena, Pignot Marc, Georgiou Mary Elizabeth, Gairy Kerry, Prevalence of lupus nephritis among patients with systemic lupus erythematosus in Germany Nephrology Dialysis Transplantation, Volume 37, Issue Supplement_3, May. 2022; 10.1093/ndt/gfac071.036.
Ding Bo, Pignot Marc, Garal-Pantaler Elena, Villinger Beate, Desta Barnabas, Golam Sarowar, Stirnadel-Farrant Heide, Marinoska Tatjana, Schefzyk Sebastian, Schwarting Andreas, Corticosteroid Use in Patients With Systemic Lupus Erythematosus in Germany: The CHAMOMILE Claims Database Study. DGRh 2022, Berlin, Germany 31 August–3 September. 2022;
Ständer Sonja, Ketz Miriam, Kossack Nils, Akumo Divine, Pignot Marc, Chavda Rajeev, Gabriel Sylvie, Clinical and Economic Burden Among Patients With Prurigo Nodularis Compared To A Benchmark In Germany: A Real-World-Evidence Claims Data Study. ISPOR Europe 2022, 6 - 9 November. 2022;
Ständer Sonja, Ketz Miriam, Kossack Nils, Pignot Marc, Chavda Rajeev, Gabriel Sylvie, Disease Burden, Healthcare Resource Utilization & Treatment Pattern among Patients with Prurigo Nodularis compared to a Benchmark in Germany: A Real-World-Evidence Claims Data Study. 31st EADV Congress, Milan. 2022;
Vogelmeier Claus F., Diesing Joanna, Kossack Nils, Pignot Marc, Friedrich Felix W., COPD Exacerbation History and Impact on Future Exacerbations – 8-Year Retrospective Observational Database Cohort Study from Germany. International Journal of Chronic Obstructive Pulmonary Disease. 2021; 2407–2417.
Schultze Michael, Garal-Pantaler Elena, Pignot Marc, Carnarius H., Gairy Kerry, Levy R., Economic Burden of Organ Damage in Systemic Lupus Erythematosus: Results From a German Claims Analysis. DGRh Kongress. 2021; 10.3205/21dgrh064.
Schultze Michael, Garal-Pantaler Elena, Pignot Marc, Carnarius H., Levy R., Gairy Kerry, The Burden of Organ Damage Among Patients With Systemic Lupus Erythematosus in Germany. International Congress on Systemic Lupus Erythematosus. LUPUS & CORA 2021. 2021;
Schwarting Andreas, Friedel H., Garal-Pantaler Elena, Pignot Marc, Wang X., Nab H., Desta Barnabas, Hammond E. R., The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization. Rheumatol Ther.. 2021; 10.1007/s40744-021-00277-0.
Bögemann Martin, Zagorska Aleksandra, Akumo Divine, El Hadad Laila, Pignot Marc, Using Data from a Sickness Fund Claims Database to Assess the Treatment Patterns and Healthcare Resource Utilization among Patients with Metastatic Renal Cell Carcinoma in Germany Urologia Internationalis. 2020; 10.1159/000509973.
Ständer Sonja, Ketz Miriam, Kossack Nils, Akumo Divine, Pignot Marc, Gabriel Sylvie, Chavda Rajeev, Epidemiology of Prurigo Nodularis compared with Psoriasis in Germany: A Claims Database Analysis. Acta Dermato-Venereologica. 2020; 100 (18): adv00309. 10.2340/00015555-3655.
Kossack Nils, Schoenfelder T., Schultze Michael, Pignot Marc, Mehta S., Nazareth T., Walzer S., Real-World Cost Difference in Patients With Psoriasis Initiating Apremilast vs. Secukinumab After Conventional Systemic Therapy Using German Sickness Fund Data DDK KOMPAKT 2020. JDDG Volume 18 Issue S1. 2020. 2020; 10.1111/ddg.14021.
Vogelmeier Claus F., Pignot Marc, Wiklund F., Nuevo J., Telg G., Janson C., Risk of future exacerbations among COPD patients – a real-world register-based cohort study (AvoidEx). European Respiratory Journal. 2020; 10.1183/13993003.
Vogelmeier Claus F., Nuevo J., Telg G., Friedrich Felix W., Pignot Marc, Wiklund F., Janson C., Real-Life Treatment Patterns and Burden of Disease Among Patients with COPD - A Large Observational Study. American Journal of Respiratory and Critical Care Medicine. 2020; 10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A3331.
O'Kelly James, Bartsch Robert, Kossack Nils, Borchert Julia, Pignot Marc, Hadji Peyman, Real-World Effectiveness of Osteoporosis Treatments in Germany Value in Health, Volume 23. 2020; S592. 10.1016/j.jval.2020.08.1134.
Hilz M., Das Mahapatra P., Fan Q., Marczykowski F., Werner B., Pignot Marc, Bender J., Punekar R., Hamed A., Edigkaufer M., Evaluation of Treatment Patterns of Fabry Disease Utilizing Medical Claims Analyses of a German Sickness Fund Database Value in Health, VOLUME 23. 2020; SUPPLEMENT 1, S347. 10.1016/j.jval.2020.04.1321.
Birkeland Kåre I., Bodegard Johan, Norhammar Anna, Kuiper JG, Georgiado E., Beekman- Hendriks WL, Thuresson Marcus, Pignot Marc, Herings RMC, Kooy A., How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study. Diabetes Obes Metab. 2019; 10.1111/dom.13612.
Kossack Nils, Schoenfelder T., Schultze Michael, Pignot Marc, Mehta S., Nazareth T., Walzer S., Real-World Cost Difference in Patients with Psoriasis Newly Initiating Apremilast vs. Biologic Treatment after Conventional Systemic Therapy: A Retrospective Analysis of German Sickness Fund Data. Value in Health (22). 2019; 10.1016/j.jval.2019.09.2645.
Birkeland Kåre I., Bodegard Johan, Eriksson Jan W., Norhammar Anna, Thuresson Marcus, Pignot Marc, Garal-Pantaler Elena, Yajima Toshitaka, Komuro Issei, Kadowaki Takashi, Cardiorenal disease is the most common first CV manifestation in type 2 diabetes and associated with increased mortality: a large multinational observational study EASD Congress. 2019;
Birkeland Kåre I., Bodegard Johan, Eriksson Jan W., Norhammar Anna, Thuresson Marcus, Pignot Marc, Garal-Pantaler Elena, Yajima Toshitaka, Komuro Issei, Kadowaki Takashi, Cardiorenal disease is the most common first CV manifestation in type 2 diabetes and associated with increased mortality: a large multinational observational study European Association for the Study of Diabetes 55th Annual Meeting. 2019;
Schwarting Andreas, Friedel H., Garal-Pantaler Elena, Pignot Marc, Wang X., Nab H., Desta Barnabas, Hammond E. R., The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization. Rheumatol Ther. 2018; 10.1007/s40744-021-00277-0.
Kraus MR, Kleine H., Thönnes S., Pignot Marc, Sanchez Gonzalez Y., Improvement of Hepatic and Extrahepatic Complications from Chronic Hepatitis C After Antiviral Treatment: A Retrospective Analysis of German Sickness Fund Data. Infect Dis Ther.. 2018; 7(3):339-352. 10.1007/s40121-018-0205-2.
Kraus MR, Kleine H., Thönnes S., Pignot Marc, Sanchez Gonzalez Y., Clinical and Economic Burden of Hepatic and Extrahepatic Complications from Chronic Hepatitis C: A Retrospective Analysis of German Sickness Fund Data. Infect Dis Ther. 2018; Sep;7(3):327-338. 10.1007/s40121-018-0204-3.
Hammond E. R., Friedel H., Garal-Pantaler Elena, Pignot Marc, Velthuis E., Wang X., Nab H., Desta Barnabas, Schwarting Andreas, Health Care Resource Use (HRU) and Medical Costs Analyses as a Function of Systemic Lupus Erythematosus (SLE) Disease Severity: Analysis of Claims Data of a German Sickness Fund. LUPUS. 2018; 5(Suppl 1): A1–A129. 10.1136/lupus-2018-abstract.204.
Hammond E. R., Friedel H., Garal-Pantaler Elena, Pignot Marc, Velthuis E., Wang X., Nab H., Desta Barnabas, Schwarting Andreas, Health Care Resource Utilisation (HCRU) and Cost Analyses of Systemic Lupus Erythematosus (SLE) as a Function of Disease Severity: Analysis of Real-World Claims Data from a German Sickness Fund. Ann. Rheum. Dis. 2018; 10.1136/annrheumdis-2018-eular.5150.
Klein AB, Shire N, Winget M, Wang H, Wilk A, Pignot Marc, Real-World Patient Characteristics And Patterns Of Care Among Metastatic Urothelial, Head And Neck, Non-Small Cell Lung Cancer Patients Using A German Sickness Fund Claims Database Value in Health, VOLUME 20. 2017; ISSUE 9: PA473. 10.1016/j.jval.2017.08.423.
Harrow B, Konieczny A, Pignot Marc, Wilk A, Bala M, Disease Burden During The “Watchful Waiting” Period In Women With Recurrent Ovarian Cancer In Germany Value in Health, VOLUME 20. 2017; ISSUE 9: PA465-A466. 10.1016/j.jval.2017.08.381.

sidebar

Executive Team

  • Clare Barnett
  • Karl Pauls
  • Michael Schultze
  • Alfred Pauls
  • Anja Bauerfeind
  • Do Minh Thai
  • Elisabeth Finger
  • Jens A. Lange

Management Board

  • Klaas Heinemann
  • Clare Barnett
  • Marc Pignot
  • Karl Pauls
  • Johanna Poppe

Project Management Team

  • Pauline De Corte
  • Lisa Eggebrecht
  • Maria Cabral
  • Anitha Pitchika
  • Mohammed Dagher

Search

sidebar-alt

Footer

ZEG Berlin

Berlin Center for Epidemiology and Health Research

Invalidenstraße 115
10115 Berlin
Germany

Contact Us

Expertise

  • Real-World Evidence
  • Non-interventional study design
  • Post-authorization safety studies
  • Post-authorization efficacy studies
  • Cohort studies
  • Case-control studies
  • Medical Devices
  • Diagnostic tools
  • Data collection instruments

Services

  • Crisis Management
  • Consulting
  • Data Management and Biostatistics
  • Medical Writing
  • Study Management
  • Quality Assurance
  • Pharmacovigilance

ENCePP

We are a partner centre of the ENCePP scientific network which is coordinated by the European Medicines Agency. We are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. We register studies in the ENCePP E-Register of Studies, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.

General Data Protection Regulation

With a view to the introduction of the GDPR/EUDSGVO we are glad to present our newupdated privacy policy . The updated description are stored under “about us” and then “privacy policy/GDPR”. Further translation for study participants will follow contemporary.

© 2011–2023 ZEG Berlin

Impressum

Website by Laura Yeffeth.